Skip to main content

Advertisement

SpringerLink
Log in

New biologic agents: A critical appraisal

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Approval of infliximab for treatment of Crohn's disease in late 1998 was a landmark event in medical therapy for inflammatory bowel disease. This agent was the first of many promised biologic response modifiers investigated in the last half decade, a result of progress in recombinant and monoclonal technologies and improvements in large-scale production of biologic agents. The notable efficacy of infliximab also sets a benchmark against which future biologic agents might be compared. Although it will be many years until active comparisons of these agents are made through clinical trials, sufficient clinical data is now available for critical appraisal of the potential and reality of these agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Bruggemann M, Taussig MJ: Production of human antibod repertoires in transgenic mice. Curr Opin Biotechnol 1997, 8:455–458.

    Article  PubMed  CAS  Google Scholar 

  2. van Dullemen HM, van Deventer SJ, Hommes DW, et al.: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109:129–135.

    Article  PubMed  Google Scholar 

  3. McCabe RP, Woody J, van Deventer S, et al.: A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease [abstract].Gastroenterology 1996, 110:A962.

    Google Scholar 

  4. Targan SR, Hanauer SB, van Deventer SJH, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997, 337:1029–1035. The first double-blinded, placebo-controlled trial of infliximab in Crohn's disease. This study clearly demonstrates the short-term efficacy of this agent.

    Article  PubMed  CAS  Google Scholar 

  5. Rutgeerts P, D'Haens GD, van Deventer SJH, et al.: Retreatment with anti-TNFa chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease [abstract]. Gastroenterology 1997, 112:A1078. This follow-up of Targan's study [4**] provides the only available clinical trial data on repeated dosing in Crohn's disease.

    Article  Google Scholar 

  6. Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398–1405. This landmark study is the first ever to demonstrate efficacy in healing of Crohn's fistulae in a randomized, controlled trial.

    Article  PubMed  CAS  Google Scholar 

  7. Hanauer SB, Rutgeerts PJ, D'Haens G, et al.: Delayed hypersensitivity to Infliximab (Remicade) re-infusion after 2-4 year interval without treatment [abstract]. Gastroenterology 1999, 116:A731. Describes a previously unrecognized adverse effect of infliximab concomitant with long delays between courses of treatment.

    Google Scholar 

  8. Schaible TF, Braakman T, Marsters P, et al.: Long-term safety of infliximab (@#@ Anti-TNFa antibody) in patients with rheumatoid arthritis: results of the ATTRACT trial [abstract]. Gastroenterology 1999, 116:A813.

    Article  Google Scholar 

  9. D'Haens G, Van Deventer S, Van Hogezand R, et al.: Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999, 116:1029–1034.

    Article  PubMed  Google Scholar 

  10. van Dullemen HM, de Jong E, Slors F, et al.: Treatment of therapy-resistant perineal metastatic Crohn's disease after proctectomy using anti-tumor necrosis factor chimeric monoclonal antibody, cA2: report of two cases. Dis Colon Rectum 1998, 41:98–102.

    Article  PubMed  Google Scholar 

  11. Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety Inflamm Bowel Dis 1999, 5:119–133. An excellent summary of the biologic agents currently available to inhibit TNFa. An excellent summary of the biologic agents currently available to inhibit TNFa.

    Article  PubMed  CAS  Google Scholar 

  12. Stack WA, Mann SD, Roy AJ, et al.: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-a in Crohn's disease. Lancet 1997, 349:521–524.

    Article  PubMed  CAS  Google Scholar 

  13. Weinblatt ME, Kremer JM, Bankhurst AD, et al.: A trial of etanercept,a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253–259.

    Article  PubMed  CAS  Google Scholar 

  14. Moreland LW, Schiff MH, Baumgartner SW, et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999, 130:478–486.

    PubMed  CAS  Google Scholar 

  15. van Deventer SJH, Elson CO, Fedorak RN: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 1997, 113 383–389.

    Article  PubMed  Google Scholar 

  16. Fedorak RN, Gangl A, Elson CO, et al. Safety, tolerance and efficacy of multiple doses of subcutaneous interleukin-10 in mild to moderate active Crohn's disease (STEMM-CD) [abstract]. Gastroenterology 1998, 114:A974.

    Article  Google Scholar 

  17. Schreiber S, Fedorak RN, Nielsen OH, et al.: A safety and efficacy study of recombinant human interleukin-10 (rHuIL-10) treatment in 329 patients with chronic active Crohn's disease (CACD) [abstract]. Gastroenterology 1998, 114:A1080.

    Google Scholar 

  18. Schreiber S, Fedorak RN, Wild G, et al.: Safety and tolerance of rHuIL-10 treatment in patients with mild/moderate active ulcerative colitis [abstract]. Gastroenterology 1998, 114:A1080.

    Google Scholar 

  19. Sands BE, Bank S, Sninsky CA, et al.: Preliminary evaluation of safety and activity of recombinant human interleukin 1 in patients with active Crohn's disease. Gastroenterology 1999, 117:58–64.

    Article  PubMed  CAS  Google Scholar 

  20. Sands BE, Winston B, Salzberg B, et al.: A randomized, doublemasked, placebo-controlled study of recombinant human interleukin eleven (rhIL-11) in Crohn's disease subjects not receiving prednisone [abstract]. Gastroenterology 1999, 116:A811.

    Google Scholar 

  21. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al.: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998, 114:1133–1142. This is the first reported trial of an antisense oligonucleotide as a means of treating gastrointestinal disease. Although the number of treated patients was small and the treatment regimen time-intensive, the results give a hint of the promise of this new class of agents.

    Article  PubMed  CAS  Google Scholar 

  22. Gordon FH, Hamilton MI, Donoghue S, et al: Treatment of active ulcerative colitis with a recombinant humanized antibody to a4 integrin (Antegren) [abstract]. Gastroenterology 1999, 116:A726.

    Google Scholar 

  23. Gordon FH, Lai CWY, Hamilton MI, et al.: Randomized double-blind placebo-controlled trial of recombinant humanized antibody to a4 integrin (Antegren) in active Crohn's disease [abstract]. Gastroenterology 1999, 116:A726.

    Google Scholar 

  24. Sands BE: Therapy of inflammatory bowel disease. Gastroenterology 2000, in press.

Download references

Author information

Authors and Affiliations

  1. Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, GRJ 825a, 02114, Boston, MA, USA

    Bruce E. Sands MD

Authors
  1. Bruce E. Sands MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sands, B.E. New biologic agents: A critical appraisal. Curr Gastroenterol Rep 1, 470–475 (1999). https://doi.org/10.1007/s11894-999-0005-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-999-0005-7

Keywords

Search

Navigation